Genmab Current Ratio 2019-2022 | GMAB
Current and historical current ratio for Genmab (GMAB) from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Genmab current ratio for the three months ending September 30, 2022 was 9.62.
| Genmab Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$3.89B |
$0.40B |
9.62 |
| 2022-06-30 |
$3.65B |
$0.28B |
13.11 |
| 2022-03-31 |
$3.50B |
$0.20B |
17.31 |
| 2021-12-31 |
$3.62B |
$0.25B |
14.50 |
| 2021-09-30 |
$3.48B |
$0.29B |
12.00 |
| 2021-06-30 |
$3.29B |
$0.22B |
15.03 |
| 2021-03-31 |
$3.23B |
$0.21B |
15.42 |
| 2020-12-31 |
$2.88B |
$0.19B |
15.00 |
| 2020-09-30 |
$3.06B |
$0.36B |
8.64 |
| 2020-06-30 |
$2.83B |
$0.30B |
9.53 |
| 2020-03-31 |
$2.08B |
$0.11B |
19.04 |
| 2019-12-31 |
$2.09B |
$0.14B |
14.88 |
| 2019-09-30 |
$1.83B |
$0.10B |
18.72 |
| 2019-06-30 |
$1.18B |
$0.08B |
14.89 |
| 2019-03-31 |
$0.00B |
|
0.00 |
| 2018-12-31 |
$1.18B |
$0.07B |
16.77 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$25.415B |
$1.349B |
|
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
|
